umifenovir (arbidol) for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. antiviral and associated therapy
vs. lopinavir/ritonavir
vs. control
vs. standard of care

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

popup

CTRI/2020/06/025957, 0 CTRI/2020/06/025957

umifenovir (arbidol) vs. favipiravir

COVID-19 mild to moderate

ELACOI (Lopinavir/ritonavir), 2020 NCT04252885

umifenovir (arbidol) vs. lopinavir/ritonavir

COVID-19 mild to moderate

Yethindra, 2020 None

umifenovir (arbidol) vs. standard of care

COVID-19 mild to moderate

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open